3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Colorectal Neoplasms
5
Multiple Myeloma
4
Barrett Esophagus
3
Venous Thromboembolism
2
Tobacco Use Disorder
2
Prostatic Neoplasms
2
Precancerous Conditions
2
Polycythemia Vera
2
Myocardial Infarction
2
Esophageal Neoplasms
2
Colonic Neoplasms
2
Breast Neoplasms
2
Vascular Diseases
1
Triple Negative Breast Neoplasms
1
Thromboembolism
1
Thrombocytopenia
1
Thrombocythemia, Essential
1
Stroke
1
Soft Tissue Neoplasms
1
Smoking Cessation
1
Sarcoma
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Node Positive HER2 Negative Breast Cancer
1
Neoplasms, Plasma Cell
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Myocardial Ischemia
1
Myeloproliferative Disorders
1
Multiple Pulmonary Nodules
1
Interventions
Dexamethasone
32
Cyclophosphamide
30
fludarabine phosphate
25
Melphalan
25
Busulfan
25
Bortezomib
21
Tacrolimus
20
Lenalidomide
19
Peripheral Blood Stem Cell Transplantation
18
Mycophenolic Acid
17
Whole-Body Irradiation
16
Antilymphocyte Serum
16
fludarabine
14
Calcium Dobesilate
13
Thalidomide
12
Filgrastim
12
Granulocyte Colony-Stimulating Factor
11
Methotrexate
10
pomalidomide
9
Cyclosporine
8
Radiotherapy
6
Etoposide
6
Cord Blood Stem Cell Transplantation
6
Surveys and Questionnaires
5
Stem Cell Transplantation
5
Rituximab
5
Methylprednisolone
5
sargramostim
4
carfilzomib
4
Sirolimus
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Neoplasms, Plasma Cell
×
Aspirin
×
Clear all
NCT00790842
2018-10-24
PrE1003
PrECOG, LLC.
Phase 1/2
Terminated
63 enrolled
14 charts